Finance entity
Paltusotine is most often covered alongside Crinetics Pharmaceuticals, which appears in 2 of these 2 stories. The 155-day window averages about 0.1 stories each week. Each story carries 2.5 original sources on average, compared with 2.8 for the broader beat in this window.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Paltusotine is most often covered alongside Crinetics Pharmaceuticals, which appears in 2 of these 2 stories. The 155-day window averages about 0.1 stories each week. Each story carries 2.5 original sources on average, compared with 2.8 for the broader beat in this window. The 5.5 average consequence score is below the beat benchmark of 6.4 in the same window. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Finance stories mentioning Paltusotine across the period from February 27, 2026 to July 31, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 3118 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Paltusotine. Shared-story counts are live from our verified record — not editorial picks.
Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
Paltusotine is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
